Skip to content

Analysis of the effectiveness and safety of liposomal bupivacaine for postoperative transversus abdominis fascia plane block analgesia in patients undergoing cesarean section

Analysis of the effectiveness and safety of liposomal bupivacaine for postoperative transversus abdominis fascia plane block analgesia in patients undergoing cesarean section

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107988
Enrollment
Unknown
Registered
2025-08-21
Start date
2024-12-05
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean section

Interventions

Bupivacaine liposome group:1.33% bupivacaine liposomal subcostal transversus abdominis fascia plane block, 20 ml each bilaterally
Bupivacaine group:0.25% bupivacaine for subcostal border transversus abdominis fascia plane block, 20 ml each bilaterally
Bupivacaine combined with dexamethasone and dexmedetomidine group:0.25% bupivacaine combined with 5mg dexamethasone and 30ug dexmedetomidine for subcostal transversus abdominis fascia planar block, 20

Sponsors

Gansu Maternal and Child Health Hospital (Gansu Provincial Center Hospital)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: ASA classification II or III, signed informed consent. Age 18-45 years, singleton full-term pregnancy. Anesthesia was by lumbar anesthesia.

Exclusion criteria

Exclusion criteria: Those who refuse to sign the informed consent form. Those who are allergic to the study drug. Those with contraindications to lumbar anesthesia. Patients with previous history of abdominal surgery or chronic pain. Patients with a history of mental illness or inability to accurately express pain.

Design outcomes

Primary

MeasureTime frame
Pain scores at rest and during coughing at 2, 6, 12, 24, 48, and 72 hours postoperatively;Opioid Tramadol Dosage in the Postoperative Period of 72 Hours;

Secondary

MeasureTime frame
Incidence of postoperative injection site reactions, symptoms of local anesthetic toxicity and nausea, vomiting, sedation and other drug-related side effects associated with local anesthetics;Time to first postoperative bed mobility, duration of breastfeeding, and length of hospitalization;

Countries

China

Contacts

Public ContactBao Yuncheng

Gansu Maternal and Child Health Hospital (Gansu Provincial Center Hospital)

52309345@qq.com+86 151 1712 6246

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026